Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

Pfizer has agreed to acquire Arena Pharmaceuticals for about $6.7 billion in a deal that validates the San Diego biotech’s plan to reshape itself around a portfolio of inflammation drugs.